AP Biosciences, Inc. (TPEX:6945)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
112.50
-5.50 (-4.66%)
Jul 9, 2026, 1:14 PM CST
Market Cap10.86B +136.8%
Revenue (ttm)n/a
Net Income-459.05M
EPS-5.38
Shares Out 96.99M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume98,000
Open115.50
Previous Close118.00
Day's Range112.00 - 119.50
52-Week Range52.30 - 236.00
Beta-0.45
Analystsn/a
Price Targetn/a
Earnings DateAug 10, 2026

About AP Biosciences

AP Biosciences, Inc. researches and develops protein and antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 37
Stock Exchange Taipei Exchange
Ticker Symbol 6945
Full Company Profile

Financial Performance

Financial Statements